2020 Avon Court, #4
Charlottesville, VA 22902
434-220-0718
info@diffusionpharma.com
 RSS Feed
  • Home
  • About Us
    • Company History
    • Leadership Team
      • Management Team
        • David Kalergis, JD/MBA
        • John L. Gainer, PhD
        • Matthew W. Hantzmon, MBA
        • Ben Shealy, MBA/CFA
        • David R. Jones, M.D., Chief Scientific Officer
        • Kim Whitten, PharmD, RAC
        • Robert Murray, PhD
        • James Edward John, III
        • Kelly Hoy
        • Tracey Linkous Danner, CTM
      • Board of Directors
        • David Kalergis, JD/MBA
        • John L. Gainer, PhD
        • Mark T. Giles, JD
        • Thomas Byrne, JD
        • Robert W. Adams, JD
      • Scientific Advisory Board
        • John L. Gainer, PhD
        • Stuart A. Grossman, MD
        • John A. Jane, Sr., MD, Ph.D., FRCS(C), FACS
        • David R. Jones, M.D.
        • Guy M. Chisolm, Ph.D.
    • Patent Portfolio
    • News
      • Press Releases
      • Subscribe to our news
      • Key Contacts
    • Contact Us
    • Directions
  • Business Development
  • Investors
  • Pipeline
    • Patient Populations
    • Clinical Development of TSC
  • Science
    • Hypoxia and Hypoxic Conditions
    • Published Research
    • Our Scientific Collaborators

Published Research

Highlights of Animal and In-Vitro Studies for TSC:

Radiation sensitization studies show significant effects

  • Rat and mouse tumor models have been studied in conjunction with radiation therapy and TSC
  • Numerous studies compare various doses of TSC with radiation therapy versus radiation therapy alone
  • Significant improvements in survival, tumor shrinkage and tumor control seen

Hypoxia-related animal models show significant effects

  • Hemorrhagic shock: improvement in survival
  • Cardiovascular disease/stroke: reduced ischemic penumbra
  • Respiratory disorders: enhanced PO2
  • Oxygen enhancement in hyperoxic animals: allows study of TSC’s dose/response/duration of action

In vitro and in silico studies support the mechanism of action

  • Demonstrate enhanced hydrogen bonding
  • Demonstrate enhanced diffusion of both oxygen and glucose by about 30 percent
  • Alternative mechanism hypotheses do not explain increased tissue oxygen consumption

Published Research

Sheehan J, Popp B, Monteith S, Toulmin A, Tomlinson J, Martin J, Cifarelli C. Trans sodium crocetinate: functional neuro-imaging studies in a hypoxic brain tumor. J Neurosurg. DOI: 10.3171/2011.5.JNS101954, 2011.

Sheehan J, Shaffrey M, Gupta B, Larner J, Rich J, Park D. Improving the radiosensitivity of radioresistant and hypoxic glioblastoma. Future Oncology (2010)6(10), 1591-1601, 2010.

Sheehan J, Cifarelli CP, Dassoulas K, Olson C, Rainey J, Han S. Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide.Journal of Neurosurgery. 2010; 1309: 234–239.

Sheehan, J, Sherman J, Cifarelli C, Jagannathan J, Dassoulas K, Olson C, Rainey J, Han S. Effect of trans sodium crocetinate on brain tumor oxgenation . Journal of Neurosurgery. 2009;111:226-229.

Sheehan J, Ionescu A, Pouratian N, Hamilton DK, Schlesinger D, Oskouian RJ, Sansur C. Use of trans sodium crocetinate for sensitizing glioblastoma multiforme to radiation. Journal of Neurosurgery. 2008: 108(5):972-97.

Okonkwo D, Wagner J, Melon D, et al. Trans-Sodium Crocetinate Increases Oxygen Delivery to Brain Parenchyma in Rats on Oxygen Supplementation. Neuroscience Letters. 2003;352:97-100.

Hiatt W, Barz K, Gainer J, Mohler E. Evaluation of Trans Sodium Crocetinate on Safety and Exercise Performance in Patients with Peripheral Artery Disease and Intermittent Claudication. Circulation. 2010; 122:A12341.

Lapchak P; Efficacy and Safety Profile of the Carotenoid Trans Sodium Crocetinate Administered to Rabbits Following Multiple Infarct Ischemic Strokes: A Combination Therapy Study with Tissue Plasminogen Activator. Brain Res. 2010;1309:136-145.

Manabe H, Okonkwo DO, Gainer JL, Clarke RH, Lee KS. Protection against focal ischemic injury to the brain by trans-sodium crocetinate. Journal of Neurosurgery. [Epub ahead of print] 2009; Vol. 0, No. 0, Pages 1-8 (doi: 10.3171/2009.10.JNS09562). Online Podcast

Stennett A, Murray R, Roy J, Gainer J. Trans-Sodium Crocetinate and Hemorrhagic Shock. Shock. 2007: 28(3):339-344.

Gainer J, Stennett A, Murray R. The Effect of Trans Sodium Crocetinate (TSC) in a Rat Oleic Acid Model of Acute Lung Injury. Pulmonary Pharmacology and Therapeutics. 2005;18:213-216.



Home | About Us | Business Development | Investors | Pipeline | Science


BioNetwork East - Investment Challenge Winner

©2010 Diffusion Pharmaceuticals LLC
Terms of Use